Recherche PDF


Cet outil permet de trouver un fichier parmi les documents publics partagés par les utilisateurs de Fichier-PDF.fr.
Dernière mise à jour de la base de données: 21 octobre à 07:29 - Environ 390000 fichiers indexés.

Afficher résultats par page

Réponses pour «antibiotics»:



Total: 100 résultats - 0.121 secondes

Optimal duration of antibiotic treatment in Gram-negative infections 100%

De Waele a and Ignacio Martin-Loeches b Purpose of review Whilst many guidelines recommend limiting the use of antibiotics because of the increase in antimicrobial resistance (AMR), this strategy becomes challenging when dealing with severe infections in critically ill patients.

https://www.fichier-pdf.fr/2018/11/09/fichier-pdf-sans-nom/

09/11/2018 www.fichier-pdf.fr

PK PD BGN ICU 2018 98%

This study reviews the pharmacokinetic changes that occur in critically ill patients, along with the pharmacodynamics and toxicodynamics of antibiotics commonly used for the treatment of Gram-negative bacterial infections to formulate a recommendation for antibiotic dosing at the bedside.

https://www.fichier-pdf.fr/2018/11/09/pkpdbgnicu2018/

09/11/2018 www.fichier-pdf.fr

ANTIBIOTICS 2006 98%

Colleagues for Excellence reviews the objectives of endodontic treatment in managing infected root canal systems, specifically addressing antibiotics and their impact on patients.

https://www.fichier-pdf.fr/2014/02/14/antibiotics-2006/

14/02/2014 www.fichier-pdf.fr

TempVapo 96%

John M. McPartland and Ethan B.

https://www.fichier-pdf.fr/2013/11/06/tempvapo/

06/11/2013 www.fichier-pdf.fr

Chest-2011- Linezolid Vs Glycopeptide MRSA Pneumonia 91%

Linezolid vs Glycopeptide Antibiotics for the Treatment of Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia :

https://www.fichier-pdf.fr/2013/12/29/chest-2011-linezolid-vs-glycopeptide-mrsa-pneumonia/

29/12/2013 www.fichier-pdf.fr

CRE Combination versus monotherapy 89%

Keywords antibiotic resistance, combination therapy, evidence-based medicine INTRODUCTION Since Ungar’s discovery of the synergistic activity of penicillin and sulphonamides in 1943, the practice of combining antibiotics that are active in vitro to enhance their efficacy has attracted both clinicians and researchers.

https://www.fichier-pdf.fr/2018/11/09/crecombination-versus-monotherapy/

09/11/2018 www.fichier-pdf.fr

IADT 2012 Avulsions Guidelines 88%

• Administer systemic antibiotics (see Antibiotics).

https://www.fichier-pdf.fr/2013/11/08/iadt-2012-avulsions-guidelines/

08/11/2013 www.fichier-pdf.fr

Guidelines on urological infections 2015 87%

3C.4.1.3 Laboratory diagnosis 3C.4.1.4 Imaging diagnosis 3C.4.2 Disease management 3C.4.2.1 Mild and moderate cases 2 9 9 9 9 9 9 11 11 11 11 11 11 12 12 12 12 12 12 12 12 12 13 13 13 13 13 13 13 13 13 14 14 14 14 14 14 15 16 16 16 16 16 17 17 17 17 UROLOGICAL INFECTIONS - LIMITED UPDATE MARCH 2015 3C.4.2.2 Severe cases 3C.4.3 Follow-up 3C.5 Recurrent uncomplicated UTIs in adult women 3C.5.1 Diagnostic evaluation 3C.5.2 Disease management and follow-up 3C.5.2.1 Risk factors and behavioural modifications 3C.5.2.2 Non-antimicrobial prophylaxis 3C.5.2.3 Antimicrobial prophylaxis 3D COMPLICATED UTIs WITH UROLOGICAL AND NEPHROLOGICAL RISK FACTORS IN ADULTS 3D.1 Introduction 3D.2 Classification systems 3D.3 Diagnostic evaluation 3D.3.1 Clinical presentation 3D.3.2 Urine cultures 3D.3.3 Microbiology (spectrum and antibiotic resistance) 3D.3.4 Special types of complicated UTIs 3D.3.5 Special types of renal infections 3D.3.6 Complicated UTI after renal transplantation 3D.4 Disease management 3D.4.1 Choice of antibiotics 3D.4.2 Duration of antibiotic therapy 3D.4.3 Specific treatment considerations 3D.4.3.1 Adult Polycystic kidney disease 3D.4.3.2 Special types of complicated UTIs 3D.4.3.3 Special types of renal infections 3D.4.3.4 UTI in renal transplantation 3D.5 Follow-up 3E SEPSIS SYNDROME IN UROLOGY (UROSEPSIS) 3E.1 Introduction 3E.2 Epidemiology, aetiology and pathophysiology 3E.3 Classification systems 3E.4 Diagnostic evaluation 3E.4.1 Physiology and biochemical markers 3E.4.1.1 Cytokines as markers of the septic response 3E.4.1.2 Procalcitonin is a potential marker of sepsis 3E.5 Disease management 3E.5.1 Prevention 3E.5.1.1 Preventive measures of proven or probable efficacy 3E.5.1.2 Appropriate perioperative antimicrobial prophylaxis 3E.5.1.3 Ineffective or counterproductive measures 3E.5.2 Treatment 3E.5.2.1 Relief of obstruction 3E.5.2.2 Antimicrobial therapy 3E.5.2.3 Adjunctive measures 3F CATHETER-ASSOCIATED UTIs 3F.1 Introduction 3F.2 Methods 3F.3 Classification systems 3F.4 Diagnostic evaluation 3F.5 Disease management 3F.6 Summary of recommendations 3G UTIs IN CHILDREN 3G.1 Introduction 3G.2 Epidemiology, aetiology and pathophysiology 3G.3 Classification systems 3G.4 Diagnostic evaluation 3G.4.1 Physical examination 3G.4.2 Laboratory tests 3G.4.2.1 Collection of the urine 3G.4.2.2 Quantification of bacteriuria UROLOGICAL INFECTIONS - LIMITED UPDATE MARCH 2015 18 19 19 19 19 19 19 20 21 21 21 22 22 22 22 22 23 23 24 24 24 25 25 25 25 26 26 26 26 27 27 27 28 28 28 29 29 29 29 29 30 30 30 31 31 31 31 31 32 32 32 33 33 34 34 35 35 35 35 35 3 3G.4.2.3 Other biochemical markers 3G.4.3 Imaging of the urinary tract 3G.4.3.1 Ultrasound 3G.4.3.2 Radionuclide studies 3G.4.3.3 Cystourethrography 3G.4.3.4 Additional imaging 3G.4.3.5 Urodynamic evaluation 3G.4.4 Schedule of investigation 3G.5 Disease management 3G.5.1 Severe UTIs 3G.5.2 Simple UTIs 3G.5.3 Prophylaxis 3H URETHRITIS 3H.1 Introduction 3H.2 Methods 3H.3 Epidemiology, aetiology and pathogenesis 3H.4 Diagnostic evaluation 3H.5 Disease management 3H.5.1 Treatment of gonococcal urethritis 3H.5.2 Treatment of chlamydial urethritis 3H.5.3 Treatment of Mycoplasma genitalium urethritis 3H.5.4 Treatment of Ureaplasma urealyticum urethritis 3H.5.5 Treatment of Trichomonas vaginalis urethritis 3H.5.6 Treatment of non-gonococcal urethritis (NGU)* 3H.6 Follow-up 3I BACTERIAL PROSTATITIS 3I.1 Introduction 3I.2 Epidemiology, aetiology and pathogenesis 3I.3 Diagnostic evaluation 3I.3.1 History and symptoms 3I.3.1.1 Symptom questionnaires 3I.3.2 Clinical findings 3I.3.3 Urine cultures and expressed prostatic secretion 3I.3.4 Prostate biopsy 3I.3.5 Other tests 3I.3.6.

https://www.fichier-pdf.fr/2015/06/05/guidelines-on-urological-infections-2015/

05/06/2015 www.fichier-pdf.fr

Discitis1 86%

Antibiotics were given in 11 cases and but no immobilization was used.

https://www.fichier-pdf.fr/2012/04/14/discitis1/

14/04/2012 www.fichier-pdf.fr

PCT Peritonite Crit Care 85%

Introduction Overuse of antibiotics is common in both medical and surgical (perioperative medicine) intensive care unit (ICU) leading to the development of antimicrobial resistance and hospitalacquired infections [1].

https://www.fichier-pdf.fr/2013/10/28/pct-peritonite-crit-care/

28/10/2013 www.fichier-pdf.fr

Discitis2 83%

In 75% of cases it demonstrated a paravertebral inflammatory mass, which helped to determine the duration of the oral therapy given after initial intravenous antibiotics.

https://www.fichier-pdf.fr/2012/04/14/discitis2/

14/04/2012 www.fichier-pdf.fr

Current management of Gram-negative septic shock 82%

Indeed, outcomes are influenced by multiple other factors including appropriateness of initial antibiotics, antimicrobial sensitivity and virulence, Department of Intensive Care, Erasme Hospital, Universite´ Libre de Bruxelles, Brussels, Belgium Correspondence to Jean-Louis Vincent, Department of Intensive Care, Erasme University Hospital, Route De Lennik 808, 1070 Brussels, Belgium.

https://www.fichier-pdf.fr/2018/11/09/current-management-of-gram-negative-septic-shock/

09/11/2018 www.fichier-pdf.fr

Article-PUGG-AVK-Drugs-and-Aging-Octobre-2013 81%

age, gender, the type of care structure, characteristics of the VKA treatment (indication for VKA, type of VKA, time since institution of VKA, results and dates of the last two INRs, history of INR [4.5, and history of major bleeding), current co-medications known to interact with VKA [aspirin, clopidogrel, NSAIDs, statins (HMG-CoA reductase inhibitors), antibiotics, antifungal drugs, proton pump inhibitors, selective serotonin reuptake inhibitors (SSRIs), and acetaminophen], and co-morbidities (Charlson’s score [28]).

https://www.fichier-pdf.fr/2017/08/03/article-pugg-avk-drugs-and-aging-octobre-2013/

03/08/2017 www.fichier-pdf.fr

Vitalac poultry presentation 79%

KARNO Liver KARNO Grow KARNO AD3EC KARNO Lyte KARNO Selen KARNO Phos Improvement of health and performances Assistance in reducing the use of medicines • Decrease of the digestive pathologies • Decrease of the mortalities • Improvement of the DWG and the FCR • Improvement of the homogeneity Reducing the use of antibiotics is a stake in public health (limiting the development of resistance to antibiotics).

https://www.fichier-pdf.fr/2016/01/06/vitalac-poultry-presentation/

06/01/2016 www.fichier-pdf.fr

Discitis3 79%

Intravenous antibiotics are administered when cultures of the disc space are posi- Introduction Intervertebral disc space inflammation is uncommon in children.

https://www.fichier-pdf.fr/2012/04/14/discitis3/

14/04/2012 www.fichier-pdf.fr

Septic shock Protocol based care NEJM 2014 edito 78%

The rate of intravenous antimicrobial administration 6 hours after randomization was approximately 97%, a finding that suggests that notification that septic shock is present encourages the administration of antibiotics.

https://www.fichier-pdf.fr/2014/03/18/septic-shock-protocol-based-care-nejm-2014-edito/

18/03/2014 www.fichier-pdf.fr

ACG Guideline AcutePancreatitis September 2013 78%

Routine use of prophylactic antibiotics in patients with severe AP and/or sterile necrosis is not recommended.

https://www.fichier-pdf.fr/2013/10/19/acg-guideline-acutepancreatitis-september-2013/

19/10/2013 www.fichier-pdf.fr

Mustapha 2006 75%

533–542, 2006 THE JOURNAL OF ORIGINAL ARTICLE ANTIBIOTICS Genomic Analyses Lead to Novel Secondary Metabolites Part 3† ECO-0501, a Novel Antibacterial of a New Class Arjun H.

https://www.fichier-pdf.fr/2016/02/26/mustapha-2006/

26/02/2016 www.fichier-pdf.fr

Fiche REA-R-V HD 75%

Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial):

https://www.fichier-pdf.fr/2011/11/03/fiche-rea-r-v-hd/

03/11/2011 www.fichier-pdf.fr

Postdoc-position-DifKin-V2 73%

We already showed that PrkC plays a key role in the envelope homeostasis and in the resistance to antimicrobial compounds including antibiotics promoting C.

https://www.fichier-pdf.fr/2017/10/16/postdoc-position-difkin-v2/

16/10/2017 www.fichier-pdf.fr

Febrile infant update 73%

high-risk infants generally receive empiric antibiotics and possibly admission.

https://www.fichier-pdf.fr/2017/07/28/febrile-infant-update/

28/07/2017 www.fichier-pdf.fr

BIOTOXIN PROTOCOL2082363964 (2) 72%

These bacteria form a biofilm making it hard for many antibiotics to penetrate, sheltering bacteria.

https://www.fichier-pdf.fr/2017/03/30/biotoxin-protocol-pdf2082363964-2/

30/03/2017 www.fichier-pdf.fr

Peds0415 Septic Shock 71%

Providing oxygen, improving tissue perfusion through augmentation of cardiac output, and administering antibiotics in a timely manner have all been shown to significantly improve outcomes in children with septic shock.

https://www.fichier-pdf.fr/2017/09/16/peds0415-septic-shock/

16/09/2017 www.fichier-pdf.fr